Want to see ICCM full AI Analyst Report?
ICCM Stock Chart & Stats
$3.08
-$0.13(-4.22%)
At close: 4:00 PM EDT
$3.08
-$0.13(-4.22%)
Day’s Range― - ―
52-Week Range$2.12 - $42.00
Previous CloseN/A
Volume71.33K
Average Volume (3M)6.80M
Market Cap
$6.82M
Enterprise Value$4.71
Total Cash (Recent Filing)$12.03M
Total Debt (Recent Filing)$90.00K
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Nov 25, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.72
Shares Outstanding2,806,701
10 Day Avg. Volume88,929
30 Day Avg. Volume6,795,886
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)4.28
Price to Sales (P/S)11.48
P/FCF Ratio-2.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.75Price Target Upside1255.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.57
Revenue Forecast (FY)$4.53M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption And Recurring UtilizationExpansion of the U.S. installed base and higher disposable probe use indicate growing physician adoption and a recurring consumables opportunity. This can support durable revenue growth as more systems become active and procedure volumes increase.
Strengthening Clinical Evidence And Market AcceptanceLong-term clinical data, peer-reviewed publications and inclusion in professional guidance can reduce adoption barriers for a medical device. Broader clinical credibility may support physician training, patient acceptance and expansion into additional indications.
Low Leverage And Improved LiquidityMinimal leverage limits interest and solvency pressure, while the enlarged cash balance provides funding capacity for commercialization, clinical studies and reimbursement work. This improves financial flexibility during the company’s scaling phase.
Bears Say
Persistent Losses And Negative Cash GenerationSubstantial losses and ongoing cash burn show that current revenue is insufficient to fund operations. Continued investment in sales, research and clinical programs may require additional capital before the business can demonstrate sustainable operating leverage.
Reimbursement Remains UnresolvedUncertain reimbursement can slow physician adoption and limit procedure volumes even when clinical evidence is favorable. Until coverage and payment pathways become clearer, the commercial opportunity remains dependent on provider economics and execution.
Ongoing Dilution And Financing DependenceEquity-based compensation and repeated financing instruments can increase the fully diluted share count while the company remains cash-flow negative. This may reduce existing holders’ ownership and reflects reliance on external funding to support growth.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $2.12 and its highest was $42.00 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $6.82M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 92 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on Aug 12, 2026. The company reported -$1.545 earnings per share for the quarter, missing the consensus estimate of -$1.517 by -$0.028.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -1.16.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 2,806,701 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$1.545 in its last earnings report, missing expectations of -$1.517. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Icecure Medical Ltd.
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
ICCM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive growth story: significant top‑line growth (≈45% YoY), meaningful expansion of the U.S. commercial installed base (~70% growth, >30 active sites), rising recurring utilization, positive clinical results and publications, and a strengthened cash position (~$12M) after financing. These operational and clinical advances are tempered by an increased net loss (H1 2026: $8.8M), higher operating expenses to fund commercialization and R&D, foreign exchange headwinds that compressed margins, and remaining uncertainty around reimbursement timelines and CHOICE enrollment timing. On balance, the company appears to be transitioning into a commercial growth phase with near‑term execution and reimbursement risks that are being actively managed.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$41.75
▲(1255.52% Upside)
Technical Analysis
Ownership Overview
23.53% Insiders
1.44% Mutual Funds
1.90% Other Institutional Investors
73.13% Public Companies and
Individual Investors